0001855485-24-000006.txt : 20240606 0001855485-24-000006.hdr.sgml : 20240606 20240605181837 ACCESSION NUMBER: 0001855485-24-000006 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240606 DATE AS OF CHANGE: 20240605 EFFECTIVENESS DATE: 20240606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Calidi Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001855485 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 862967193 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-515263 FILM NUMBER: 241023307 BUSINESS ADDRESS: STREET 1: 4475 EXECUTIVE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-794-9600 MAIL ADDRESS: STREET 1: 4475 EXECUTIVE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: First Light Acquisition Group, Inc. DATE OF NAME CHANGE: 20210406 D 1 primary_doc.xml X0708 D LIVE 0001855485 Calidi Biotherapeutics, Inc. 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA CALIFORNIA 92121 858-794-9600 DELAWARE First Light Acquisition Group, Inc. Corporation true 2021 Allan Camaisa 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Executive Officer Director Andrew Jackson 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Executive Officer Boris Minev 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Executive Officer Wendy Pizarro 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Executive Officer Alan R. Stewart 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Director Scott Leftwich 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Director George Ng 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Director James A. Schoeneck 4475 Executive Drive, Suite 200 San Diego CA CALIFORNIA 92121 Director Biotechnology Decline to Disclose 06b false 2024-06-03 false true true false 0 LADENBURG THALMANN & CO. INC. 505 None None 640 5TH AVENUE 4TH FLOOR NEW YORK NY NEW YORK 10019 CA CALIFORNIA NV NEVADA NY NEW YORK false 5549588 5549588 0 Based on reduced exercise price of $0.20 of 10698000 existing warrants exercised, common stock issuable upon exercise of 10698000 inducement warrants at $0.30/share, common stock issuable upon exercise of 534900 placement agent warrants at $0.375/share. false 9 393152 0 Represents fee of 8% and management fee of 1% of gross proceeds received from exercise of existing warrants, and warrants to purchase up to 5% of common stock underlying the inducement warrants at exercise price of $0.375/share. 0 false Calidi Biotherapeutics, Inc. /Andrew Jackson/ Andrew Jackson Chief Financial Officer 2024-06-05